[Application of serum type III procollagen peptide level in the diagnosis of lung fibrosis developed during bleomycin treatment in cancer patients].
I
I
Okazaki
K
K
Miura
S
S
Ohya
M
M
Murakami
N
N
Nagata
K
K
Maruyama
T
T
Kobayashi
F
F
Okuno
S
S
Oda
H
H
Ito
D000328:Adult; D000368:Aged; D001761:Bleomycin / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood*; D011347:Procollagen / Q000097:blood*; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000175:diagnosis*
D010446:Peptide Fragments; D011347:Procollagen; C041876:procollagen Type III-N-terminal peptide; D001761:Bleomycin